Greek drugmakers group SFEE analysis of public hospital debt to the sector shows this reached 3.52 billion euros at end Oct 2009
The Hellenic Association of Pharmaceutical Companies (SFEE) has collected and analysed all the available data relating to pharmaceutical debts of public hospitals due to its member-companies. The analysis resulted in a set of tables, which describe in detail the overall amount due per public hospital, as well as the average length of payment delay.
The main points resulting from the analysis of the tables are the following:
On October 31, 2009, the total amount of public hospitals' debt towards SFEE's member companies was 3.52 billion euros ($5.05 billion). This shows a remarkable 31.5% increase compared to the respective figure on December 31, 2008, of 2.68 billion euros. If the rate of increase remains unchanged, it is anticipated that, by the end of 2010, hospital debts will exceed 4.5 billion euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze